Arcutis Biotherapeutics, Inc. (ARQT) stock
ARQTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/30403% above fair value
$27.33+0.18 (+0.66%)
Close on Nov 17, 2026Market cap $3.44BP/E 124.2Yield –
Arcutis Biotherapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Arcutis Biotherapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was $39.31M. For fiscal 2025 it was -$5.63M. The highest annual figure on record is -$5.63M in fiscal 2025.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$5.63M | – |
| FY2024 | Dec 31, 2024 | -$112.16M | – |
| FY2023 | Dec 31, 2023 | -$247.06M | – |
| FY2022 | Dec 31, 2022 | -$257.72M | – |
| FY2021 | Dec 31, 2021 | -$174.63M | – |
| FY2020 | Dec 31, 2020 | -$113.03M | – |
| FY2019 | Dec 31, 2019 | -$42.84M | – |
| FY2018 | Dec 31, 2018 | -$14.09M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $12.64M | +3800.9% |
| Q1 FY2026 | Mar 31, 2026 | $2.24M | – |
| Q4 FY2025 | Dec 31, 2025 | $26.19M | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.75M | – |
| Q2 FY2025 | Jun 30, 2025 | $324.00K | – |
| Q1 FY2025 | Mar 31, 2025 | -$30.38M | – |
| Q4 FY2024 | Dec 31, 2024 | -$748.00K | – |
| Q3 FY2024 | Sep 30, 2024 | -$34.69M | – |
| Q2 FY2024 | Jun 30, 2024 | -$45.12M | – |
| Q1 FY2024 | Mar 31, 2024 | -$31.60M | – |
| Q4 FY2023 | Dec 31, 2023 | -$56.24M | – |
| Q3 FY2023 | Sep 30, 2023 | -$43.98M | – |
| Q2 FY2023 | Jun 30, 2023 | -$66.49M | – |
| Q1 FY2023 | Mar 31, 2023 | -$80.34M | – |
| Q4 FY2022 | Dec 31, 2022 | -$71.07M | – |
| Q3 FY2022 | Sep 30, 2022 | -$67.70M | – |
| Q2 FY2022 | Jun 30, 2022 | -$61.98M | – |
| Q1 FY2022 | Mar 31, 2022 | -$56.98M | – |
| Q4 FY2021 | Dec 31, 2021 | -$51.71M | – |
| Q3 FY2021 | Sep 30, 2021 | -$40.88M | – |
| Q2 FY2021 | Jun 30, 2021 | -$35.83M | – |
| Q1 FY2021 | Mar 31, 2021 | -$46.20M | – |
| Q4 FY2020 | Dec 31, 2020 | -$32.57M | – |
| Q3 FY2020 | Sep 30, 2020 | -$33.69M | – |
| Q2 FY2020 | Jun 30, 2020 | -$25.76M | – |
| Q1 FY2020 | Mar 31, 2020 | -$21.01M | – |
| Q4 FY2019 | Dec 31, 2019 | -$16.80M | – |
| Q3 FY2019 | Sep 30, 2019 | -$10.72M | – |
| Q2 FY2019 | Jun 30, 2019 | -$8.24M | – |
| Q1 FY2019 | Mar 31, 2019 | -$7.07M | – |
See a number that looks wrong?